Traws Pharma, Inc. (TRAW) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Traws Pharma is a clinical-stage biopharmaceutical company focused on respiratory viral diseases (influenza, bird flu, COVID-19) and oncology. The company operates as a single segment and is classified as a non-accelerated filer and a smaller reporting company. As of May 12, 2026, there were 15,150,669 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $57,000 |
| Net Loss | $(7,107,000) | $21,490,000 (Income) |
| Diluted EPS (Common) | $(0.53) | $2.09 |
| Operating Expenses | $6,946,000 | $5,260,000 |
| Cash and Equivalents (End of Period) | $3,133,000 | $15,937,000 |
| Working Capital Deficit | $(7,543,000) | Not Reported |
| Accumulated Deficit | $(647,091,000) | $(627,664,000) |
Cash Flow: Net cash used in operating activities was $2.6 million. Net cash provided by financing activities was $1.9 million, primarily from an At-The-Market (ATM) offering.
Material Changes vs. Prior Period
- Profitability Shift: The company swung from a net income of $21.5 million in Q1 2025 to a net loss of $7.1 million in Q1 2026. The prior year income was driven by a $26.5 million non-cash gain from the change in fair value of warrant liabilities, which reversed to a $159,000 loss in the current period.
- Expense Growth: Total operating expenses increased by $1.7 million (32%). Research and Development (R&D) expenses rose 96% to $4.9 million, driven by virology program development (ratutrelvir and tivoxavir marboxil). General and Administrative (G&A) expenses decreased by 26% to $2.0 million.
- Liquidity Decline: Cash balances decreased by $687,000 during the quarter, dropping from $3.8 million to $3.1 million. Accounts payable increased by $2.0 million to $7.7 million.
Outlook, Risks, and Unusual Items
- Going Concern Warning: Management states there is substantial doubt about the company's ability to continue as a going concern for at least 12 months following the report date. Current cash is insufficient to fund operations without additional financing.
- Subsequent Financing: In April 2026 (post-period), the company completed a financing transaction with gross proceeds of up to $60.0 million. This included $10.0 million in upfront cash and milestone-based warrants for an additional $50.0 million potential proceeds.
- Regulatory Status: The FDA placed the U.S. IND for tivoxavir marboxil on clinical hold due to toxicology data concerns. The company is working to resolve this by the end of 2026. Conversely, the company reported positive interim Phase 2 data for ratutrelvir (COVID-19) showing no viral rebound events.
- Legal Contingency: The company is involved in arbitration with a former executive (Dr. Steven Fruchtman) regarding severance. The estimated loss range is $0 to $1.5 million; no reserve has been recorded.
Investor Verification Checklist
- Financing Terms: Verify the specific terms and exercise conditions of the milestone-based warrants issued in the April 2026 financing to assess the likelihood of realizing the full $60 million potential.
- FDA Clinical Hold: Monitor the status of the FDA clinical hold on tivoxavir marboxil and the timeline for resolution, as this is critical for the primary respiratory program.
- Cash Burn Rate: Assess the updated cash runway post-April financing against the projected burn rate for the ratutrelvir Phase 2 study and ongoing operations.
- Legal Exposure: Track the arbitration proceedings with Dr. Fruchtman to determine if the $1.5 million potential liability materializes.
- Warrant Liability Volatility: Review the fair value assumptions for the remaining Series A Warrants, as changes in stock price or volatility can significantly impact reported net income/loss.